Moderna announced on Wednesday that the first participant has been dosed in the company's Phase 2 clinical trial of a COVID-19 vaccine booster shot that is specific to the Omicron variant.
"We are reassured by the antibody persistence against Omicron at six months after the currently authorized 50 μg booster of mRNA-1273. Nonetheless, given the long-term threat demonstrated by Omicron's immune escape, we are advancing our Omicron-specific variant vaccine booster candidate and we are pleased to begin this part of our Phase 2 study," CEO Stéphane Bancel said in a news release, according to CNN.
Read more